The diagnoses of ALS in the New York Yankees first baseman Lou Gehrig-nicknamed "The Iron Horse" because of his remarkable streak of playing in 2,130 consecutive games-in 1939 brought national and international attention to the disease. After ALS took his life at the age of 37, the illness became known as "Lou Gehrig's disease." Other well-known people who are struggling with or have died from ALS include Mao Tse-tung, Stephen Hawking, Charles Mingus, and David Niven.
Tuesdays with Morrie, the bestselling memoir about author Mitch Albom's conversations with his former sociology professor Morrie Schwartz, depicted the disease's devastating impact.
In 1962, the British neurologist Walter Russell Brain, introduced the concept of "motor neuron disease," a group of diseases of which ALS is the most common. In the sixth edition of his book Brain, published in 1962, he made it clear that the three syndromes: upper motor neuron Cerebrum May 2017 3 degeneration, lower motor neuron degeneration, and mixed upper motor and lower motor neuron degeneration should be regarded as manifestations of the same underlying disorder. 3 ALS has been artificially distinct from other motor neuron diseases in the sense that it occurs both sporadically (sALS) and within families (familial ALS, fALS). Although some feel this distinction is practical, others feel it is artificial, since ALS is now believed to be an umbrella term for many different forms of the motor neuron disorder (just as there are various types of flu).
Today, ALS diagnosis remains difficult because these diverse forms involve a spectrum of manifestations whose heterogeneity extends to the site of onset, the degree of upper and lower motor neuron involvement, the rate of motor progression, and the presence and severity of cognitive and behavioral symptoms.
The enormous progress made in both technology and genetics over the past 20 years has led to the discovery of the first genetic mutation that causes ALS and the identification of more than 100 ALSrelated genes. These advances have helped us understand the polymorphous nature of the disease, and the ambiguity between sporadic and familial forms of ALS.
Still, no known cure exists for ALS. In the last decade alone, 18 clinical and preclinical trials have failed, most recently with a drug called dexpramipexole, which cost the US-based company Biogen $100 million to develop and test. Today, only two drugs are approved by the US Food and Drug Administration (FDA) for treating ALS symptoms. The first, approved in 1995, is Rilutek (riluzole), a costly neuroprotective medication first discovered in the 1940s. It minimally improves bulbar muscle (involved in speech and swallowing) and limb function, but not general muscle strength.
Rilutek is relatively safe and probably prolongs median survival by about two to three months. 4 Chinese clinicians recently confirmed its modest beneficial effect. 5 The second drug, known as either edaravone (Radicava) or MCI-186, was first approved in Japan in
2015
§ and then approved by the FDA on May 5, 2017. An anti-oxidant that works in the central nervous system as a potent scavenger of oxygen radicals, 7 patients in treatment experienced a placebo. In Belgium, the country where I work, a patient association called Belgian ALS League found that the intravenous injection necessary to administer the drug presents a "high burden"
and renders the drug "less attractive."
A Cultural Phenomenon
The Ice Bucket Challenge was a campaign to raise money for charity that took the internet by The consensus is that the disease arises not from the mutant enzymes' loss of its protective easier to design effective treatments."
13 Excellent recent studies have described the application of genetic methods in discovering new ALSrelated genes. [14] [15] [16] The list (last updated in 2015), with chromosomal location of the ALS related genes, can be seen at http://alsod.iop.kcl.ac.uk/Chromosomes/chromoALL.aspx.
ALS-related Genes
As human beings we are unique; shaped by our environment and life experiences but also by our genetic make-up. Human genetic diversity is associated with phenotypic variation, notably in our physical characteristics but also in determining our susceptibility and response to disease, often as part of a multi-factorial disease process. The most common form of genetic diversity are single nucleotide differences, a spelling change in the DNA code where one nucleotide is replaced by another but other larger structural variants are also being identified.
The challenge amidst so much genetic variation-there are over 10 million single nucleotide differences alone among humans-is to define specific variants responsible for common multifactorial diseases such as infections, diabetes, or heart disease. There have been major advances in how we define the genetic determinants of common disease over the last few years based on using many hundreds of thousands of genetic markers across the genome to look for association with disease in "genome-wide association studies." Nevertheless, a major challenge remains once a region of the genome has been implicated in disease to then define the specific functionally important causative variants.
High-throughput DNA sequencing technologies have generated large amounts of sequence data very rapidly and at a substantially lower cost. While these technologies provide unprecedented opportunities to discover new genes and variants underlying human disease, it should be stressed that these discoveries must be rigorously performed and replicated to prevent the proliferation of false-positive findings. A set of guidelines addresses the types of issues to consider in rare variant analysis. 17 These guidelines help provide objective, systematic, and quantitative evaluation of the evidence for pathogenicity. Moreover, sharing of these evaluations and data among research and clinical laboratories will maximize the chances that disease-causing genetic variants are correctly differentiated from the many rare non-pathogenic variants seen in all human genomes. This is particularly true for ALS, in which rare and potentially pathogenic variants in known ALS genes occur in over 25 percent of apparently sporadic and 64 percent of familial patients. The recent work of Janet Cady and others showed that a significant number of subjects carried variants Cerebrum May 2017 7 in more than one gene. This finding suggests an explanation for the varied age of symptom onset, and supports oligogenic inheritance (when a few genes cause or modulate a disease) as relevant to ALS pathogenesis. 18 Genome-wide association studies, which aim to identify common variants, have been successful in characterizing novel genetic regions associated with complex traits seen in neurodegenerative diseases such as Alzheimer or Parkinson diseases. 19 A key discovery related to ALS was the genetic variation observed at the same position (locus) on chromosome 9 that causes sporadic ALS and familial ALS-frontotemporal dementia. 20 This indicates that some of the genes that may cause ALS are pleiotropic, meaning that the same genetic mutations may produce different clinical phenotypes. The determinants of this pleiotropy are largely unknown. 21 The two sequencing methods used in ALS research are:
• Exome sequencing, also known as whole exome sequencing (WES or WXS), a technique for sequencing the expressed genes in a genome. This approach identifies genetic variants that alter protein sequences. It costs much less than whole-genome sequencing and is thus a good choice when whole-genome sequencing is not practical or necessary. It may be extended to target functional nonprotein coding elements (e.g., microRNA, long intergenic noncoding RNA, etc.) 22 Since these variants can be responsible for both Mendelian and common polygenic diseases, such as Alzheimer's disease, whole exome sequencing has been applied both in academic research and as a clinical diagnostic. It has rapidly become the primary method for the discovery of causative genes in rare diseases.
With exome sequencing, Elizabeth T. Cirulli and others identified more than 70 distinct pathogenic mutations across several genes; their discovery may guide future efforts to functionally characterize the role of these ALS genes. For dominantly inherited disorders where data suggest a mutation that confers a toxic activity on a protein (a toxic gain of function), lowering levels of the protein is a potential approach, and antisense oligonucletoides (ASOs) is one means of doing so. 
The Next Steps
From the remarkable progress already made, there is little doubt that our understanding of the genetic basis of ALS will continue to improve through conventional genetics and enhanced association studies that identify the role of rare genetic variants, including those found in noncoding DNA. However, the success of future initiatives involving the assembly of sequence and clinical data from very large-scale cohorts will require the full translation of human genetic findings into understandable biological and clinical terms. Such efforts will undoubtedly need the cooperation of multiple stakeholders, including clinicians, biochemists, informaticians, statisticians, patient participants or partners, 31 and official agencies such as the FDA.
The FDA has, in fact, taken the initiative to prepare a guidance document, "Use of Public Human
Genetic Variant Databases to Support Clinical Validity for Next Generation Sequencing (NGS)-Based
In Vitro Diagnostics," that describes the agency's current thinking on this subject. 32 It outlines the FDA's criteria in determining whether a genetic variant database is a valid source of scientific evidence that supports the clinical validity of an NGS-based test. Upon finalization approval of this document, test developers will be able to follow these recommendations when preparing a premarket submission-just one more step forward in the fight against a disease that must be 
